Apptly's UberDoc Partners with Bryleos, Bringing Woman-Owned Cellular-Health Innovator onto the Marketplace

Rhea-AI Summary

Apptly Health Technologies (CSE: APPT, FSE: 4KL0), operator of the UberDoc direct-pay healthcare marketplace, announced a strategic partnership with Bryleos, a woman-owned life sciences company focused on NAD+ science and oral cellular-health formulations. Bryleos will join the UberDoc marketplace with a dedicated presence, giving patients and physicians direct access to its offerings.

According to Apptly, the partnership supports its broader platform strategy by extending UberDoc’s direct, transparent-access model beyond specialist care and adding another potential revenue stream. Bryleos contributes its patent-pending LathMized® NAD+ platform and states that its work is grounded in randomized, placebo-controlled human research published in peer-reviewed journals. Apptly notes UberDoc does not provide medical advice and that clinical decisions remain between patients and physicians.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Partnership adds Bryleos and its published NAD+ research to the physician-founded, surgeon-led direct-pay marketplace as Apptly broadens its platform ecosystem

Vancouver, British Columbia--(Newsfile Corp. - July 28, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "the Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced a strategic partnership with Bryleos (BioNADrx Holdings, Inc.), a woman-owned life sciences company focused on NAD+ science and oral cellular-health formulations.

Highlights:

• Marketplace Onboarding: Bryleos joins the UberDoc marketplace with a dedicated company presence, giving patients and physicians a direct line to its offerings.
• Broader Platform Reach: The partnership marks another step in executing Apptly's platform strategy, extending UberDoc's direct, transparent-access model beyond specialist care and adding a new offering to the ecosystem as the Company builds toward multiple revenue streams across the platform.
• Patent-Pending Technology: Bryleos's patent-pending LathMized® NAD+ platform is built around the metabolic changes associated with aging, recovery, and everyday cellular resilience.
• Published, Peer-Reviewed Research: Bryleos grounds its work in randomized, placebo-controlled human research, with findings published in the peer-reviewed literature.

Through this partnership, UberDoc will feature Bryleos and its offerings within its platform and communications. As with any partner it features commercially, the Company discloses that relationship in line with applicable advertising and endorsement guidelines. The Company doesn't provide medical advice - clinical and treatment decisions remain solely between patients and their physicians.

"UberDoc was built on a simple idea, that patients and physicians deserve direct, transparent access to the innovations shaping modern health," said Dr. Paula M. Muto, Founder and Interim Chief Executive Officer of the Company and a practicing vascular surgeon. "Our partnership with Bryleos reflects that same commitment. We are focused on building a trusted, transparent platform where patients and the physicians who serve them can explore credible options in one place, and we are glad to welcome Bryleos into that ecosystem."

"At Bryleos, our mission has always been to translate rigorous scientific research into meaningful support for healthy aging and cellular wellness," said Wendy Komac, Chief Executive Officer of Bryleos. "Partnering with UberDoc allows us to connect with physicians and patients through an innovative healthcare platform built on transparency, accessibility, and quality care. Together, we have an opportunity to bring the concept of precision nutrition, including science-backed NAD+ support, into more informed conversations about metabolic health and overall wellness."

"As a Board Member, I am proud that the Company is partnering with Bryleos, a woman-owned life sciences company focused on cellular health that has invested in published, peer-reviewed human research," said John Dvor, a member of the Company's Board of Directors. "Partnerships like this one expand what patients can discover on the UberDoc marketplace and reflect the standard we intend to hold for every company we bring onto the platform."

About Apptly Health Technologies Corp.

Apptly Health Technologies Corp. operates UberDoc, a direct-pay healthcare marketplace that connects patients directly with board-certified specialists at transparent, upfront prices, with no referral requirements, no insurance barriers, and no surprise bills. With more than 5,000 specialist physicians and clinicians across 55-plus specialties in all 50 states, the platform provides patients with faster access to care while enabling physicians to expand patient access and grow their practices. The Company was founded by Dr. Paula M. Muto, M.D.

About Bryleos

Bryleos (BioNADrx Holdings, Inc.) is a woman-owned life sciences company developing proprietary, orally delivered NAD+ formulations designed to support healthy cellular metabolism. Its patent-pending LathMized® NAD+ platform is built around the metabolic changes associated with aging, recovery, and everyday cellular resilience. Bryleos states that it grounds its work in randomized, placebo-controlled human research with findings published in the peer-reviewed literature. More information, including its published research, is available at bryleos.com.

Neither the Canadian Securities Exchange ("CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws, including statements regarding the anticipated benefits and scope of the partnership with Bryleos, the featuring of Bryleos on the UberDoc marketplace, and the Company's broader platform, ecosystem, and growth strategy. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," "may," "will," "should," "could," "would," and similar expressions, including the negative forms thereof. Forward-looking information is based on management's current expectations, estimates, projections, and assumptions and is subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied, including market conditions, business execution risks, regulatory considerations, and the risks described in the Company's public filings available on SEDAR+. There can be no assurance that the initiatives described in this release will achieve the results currently contemplated. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

Contacts

Investor Relations / Media

Meghna Deshraj
meghna@uber-docs.com
973-369-8052
apptlyhealthtech.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306889

FAQ

What is the new partnership between Apptly Health Technologies (ESVNF) and Bryleos announced on July 28, 2026?

Apptly Health Technologies announced a strategic partnership bringing Bryleos onto its UberDoc marketplace. According to Apptly, Bryleos gains a dedicated presence, giving patients and physicians direct access to its cellular-health offerings within UberDoc’s direct-pay, transparent-access healthcare platform.

How does the Bryleos partnership affect the UberDoc marketplace operated by Apptly (ESVNF)?

The partnership adds Bryleos and its NAD+-focused products to the UberDoc marketplace. According to Apptly, this extends UberDoc beyond specialist care, supports its platform strategy, and contributes to building multiple revenue streams across the direct-pay healthcare ecosystem.

What is Bryleos and what does it contribute to Apptly’s UberDoc platform (ESVNF)?

Bryleos is a woman-owned life sciences company developing orally delivered NAD+ formulations. According to Bryleos, it offers a patent-pending LathMized® NAD+ platform built around metabolic changes with aging, recovery, and cellular resilience, and grounds its work in randomized, placebo-controlled human research.

Does the Apptly–Bryleos partnership on UberDoc involve medical advice or treatment decisions?

Apptly states that UberDoc does not provide medical advice and clinical decisions remain between patients and physicians. According to Apptly, it features Bryleos commercially with disclosed relationships, following applicable advertising and endorsement guidelines on its direct-pay healthcare marketplace.

How does Apptly’s UberDoc marketplace (ESVNF) work for patients and physicians in this Bryleos collaboration?

UberDoc connects patients directly with board-certified specialists at transparent, upfront prices without referrals or insurance barriers. According to Apptly, adding Bryleos gives those patients and physicians a direct line to science-based cellular-health offerings within the same marketplace environment.

What role does NAD+ research play in the Apptly–Bryleos partnership for UberDoc (ESVNF)?

Bryleos emphasizes NAD+ science and oral cellular-health formulations within the partnership. According to Bryleos, its LathMized® NAD+ platform and published randomized, placebo-controlled human research underpin the offerings that will be featured to patients and physicians on the UberDoc marketplace.